BAX vs DVA
BAX: Baxter International is a leading medical technology company delivering critical life-sustaining therapies for patients with complex medical conditions in hospitals and at home. DVA: DaVita is a specialized healthcare provider focused on delivering life-sustaining dialysis and integrated kidney care services to patients with chronic kidney failure.
Side-by-side fundamentals
| Metric | BAX | DVA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $23.90 | $177.02 | |
| Market cap | $12.4B | $11.3B | |
| P/E as of 2026-10-08 | n/a | 14.50 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 0.77 | |
| Net margin FY2025, SEC XBRL | -8.5% | +5.5% | DVA higher |
| Gross margin FY2025, SEC XBRL | +30.1% | n/a | |
| Operating margin FY2025, SEC XBRL | -2.7% | +15.0% | DVA higher |
| ROE FY2025, SEC XBRL | -15.7% | n/a | |
| ROA FY2025, SEC XBRL | -4.8% | +4.3% | DVA higher |
| Debt / equity as of 2026-09-03 | 1.52 | 77.99 | BAX lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.4% | +6.5% | DVA higher |
| Revenue CAGR (3y) SEC XBRL | +3.8% | +5.5% | DVA higher |
| Dividend yield as of 2026-09-03 | +0.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | 0 | BAX higher |
| Beta as of 2026-09-03 | 0.94 | 0.34 | |
| 1-year return as of 2026-10-08 close | +5.1% | +38.4% | DVA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.